Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.

Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I, Danenberg E, Ioannidou K, Kandalaft L, Coukos G, Hoves S, Ries CH, Fuertes Marraco SA, Foukas PG, De Palma M, Speiser DE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan3311. doi: 10.1126/scitranslmed.aan3311.

PMID:
29643229
2.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

3.

Reprogramming Tumor Blood Vessels for Enhancing Immunotherapy.

Schmittnaegel M, De Palma M.

Trends Cancer. 2017 Dec;3(12):809-812. doi: 10.1016/j.trecan.2017.10.002. Epub 2017 Oct 27. Review.

PMID:
29198436
4.

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

Schmittnaegel M, Rigamonti N, Kadioglu E, Cassará A, Wyser Rmili C, Kiialainen A, Kienast Y, Mueller HJ, Ooi CH, Laoui D, De Palma M.

Sci Transl Med. 2017 Apr 12;9(385). pii: eaak9670. doi: 10.1126/scitranslmed.aak9670.

PMID:
28404865
5.

A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.

Schmittnaegel M, Hoffmann E, Imhof-Jung S, Fischer C, Drabner G, Georges G, Klein C, Knoetgen H.

Mol Cancer Ther. 2016 Sep;15(9):2130-42. doi: 10.1158/1535-7163.MCT-16-0207. Epub 2016 Jun 28.

6.

Activation of cytomegalovirus-specific CD8+ T-cell response by antibody-mediated peptide-major histocompatibility class I complexes.

Schmittnaegel M, Klein C, Levitsky V, Knoetgen H.

Oncoimmunology. 2015 May 29;5(1):e1052930. eCollection 2016.

7.

Committing Cytomegalovirus-Specific CD8 T Cells to Eliminate Tumor Cells by Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules.

Schmittnaegel M, Levitsky V, Hoffmann E, Georges G, Mundigl O, Klein C, Knoetgen H.

Cancer Immunol Res. 2015 Jul;3(7):764-76. doi: 10.1158/2326-6066.CIR-15-0037. Epub 2015 Feb 17.

Supplemental Content

Loading ...
Support Center